TOTAL VOLUME:

$134.2b

24H VOL:

$126,324,530

24H TRANSACTIONS:

2,388,728,490

OPEN INTEREST:

$1,434,646,834

406,019

Markets across

30,401

events

MATCHED EVENTS:

2,689

PLATFORM COVERAGE:

5

Polymarket:

39%

VS.

Kalshi:

61%

BETA
Dashboards
Insights
Indices
Tour
All
Trending
Breaking
New
Ending Soon
Politics
Sports
Crypto
Companies
Elections
Financials
Economics
Other
Entertainment
Science and Technology
PSG vs Slovan Bratislava: First Half Spread
kalshi

PSG vs Slovan Bratislava: First Half Spread

Volume:
$80,142

PSG wins the 1H by more than 1.5 goals

 - Kalshi

PSG wins the 1H by more than 1.5 goals - Kalshi

1W

News

Positive

Negative

Neutral

Hover marker for details

Vol.

·

Resolved Sep 9, 2026

Closed: Sep 9, 3:57 PM EST

kalshi

Kalshi

View
Join Kalshi and score $25 for your first trade.
Outcome
Trade
Chance %
Price
Spread
Liquidity
Volume
24h
7d
Open Interest
Ends in
Result
kalshi

PSG wins the 1H by more than 1.5 goals

View
100%
52%
Yes 100¢No 0¢
100¢
N/A
$63,752
N/A
N/A
$31,131
Settled
Yes
kalshi

Slovan Bratislava wins the 1H by more than 1.5 goals

View
0%
1%
Yes 0¢No 100¢
100¢
N/A
$16,389
N/A
N/A
$16,389
Settled
No
Total markets: 2

Description

This market focuses on the first-half performance of PSG against Slovan Bratislava in their Champions League match. It evaluates whether either team secures a decisive lead, defined as more than a one-goal advantage, before halftime. The outcome hinges purely on the score difference at the end of the first half.

Kalshi

The event determines whether either PSG or Slovan Bratislava wins the first half by more than a 1.5 goal margin in their scheduled Champions League match. If PSG achieves this margin, the market resolves positively for the first condition. Conversely, if Slovan Bratislava attains the same margin, the market resolves positively for the second condition. Only goals scored during the first half are considered. Should the match be canceled or rescheduled beyond 48 hours, the market resolves to a fair price, ensuring equitable treatment for all participants based on these synthesized rules.